# AVZO-1418

Source: https://onco.cc/drugs/avzo-1418/  
OnCo record `avzo-1418` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AVZO-1418 is an experimental antibody-drug conjugate that targets two proteins, EGFR and HER3, on cancer cells. Avenzo Therapeutics licensed it from DualityBio and is testing it in a first phase 1/2 trial in advanced solid tumours.

## Summary

AVZO-1418, also called DB-1418, is an antibody-drug conjugate that binds two targets, EGFR and HER3, and carries a topoisomerase I inhibitor payload; DualityBio built it on its Duality Innovative Bispecific Antibody Conjugate (DIBAC) platform. Avenzo Therapeutics and DualityBio announced an exclusive licence on 7 January 2025 giving Avenzo rights outside Greater China, with USD 50 million upfront and up to about USD 1.15 billion in milestones; at that point the drug was in studies before human testing. AVENTINE-1 (NCT07038343), sponsored by Avenzo with DualityBio as collaborator, is a phase 1/2 trial that started in June 2025 in locally advanced or metastatic epithelial solid tumours, with the drug given alone and possibly with other medicines. No results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: DB-1418; AVZO-1418/DB-1418
- Tags: pipeline; deal-asset
- Code: DB-1418
- Modality: Bispecific antibody-drug conjugate (EGFR x HER3, topoisomerase I inhibitor payload)
- Mechanism: An antibody that binds both EGFR and HER3 on cancer cells carries a topoisomerase I inhibitor, a chemotherapy that breaks DNA, into those cells. It was built on DualityBio's DIBAC bispecific conjugate platform.

## Sources

- Avenzo and DualityBio licence announcement, 7 January 2025 (BioSpace copy): https://www.biospace.com/press-releases/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate
- ClinicalTrials.gov: AVENTINE-1 (NCT07038343): https://clinicaltrials.gov/study/NCT07038343

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [HER3](https://onco.cc/targets/her3/)
- companies: [Avenzo Therapeutics](https://onco.cc/companies/avenzo/), [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)
- trials: [AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)](https://onco.cc/trials/nct07038343/)

---
JSON: https://onco.cc/api/v1/entities/avzo-1418.json